Furthermore, another randomized placebo-controlled, 12-week clinical trial in 72 overweight individuals and individuals with obesity, all of which had type 1 diabetes as comorbidity, showed that the addition of an either high (1.2 and 1.8 mg) or low (0.6 mg) liraglutide dose to insulin therapy resulted in significant weight reduction (NCT01722266) [29]. This evidence concerns the gene INS and obesity disorder.